In this article
Merck
said on Monday it would split its human-health business into two units, creating a division for its cancer franchise led by blockbuster drug Keytruda while grouping its non-oncology medicines separately.
The restructuring underscores the U.S. drugmaker’s push to diversify beyond Keytruda amid the drug’s looming loss of exclusivity later this decade.
Keytruda, approved for several forms of cancer, is the best-selling prescription medicine in the world. The treatment generated more than $30 billion in 2025 and accounted for nearly half of the company’s total revenue.
